Current Trials
AHCC12 & AHCC13 |
Precision Medicine in Liver Cancer across an Asia Pacific Network 2.0 (PLANet 2.0) (NCT05516628) AHCC12: Deep, Multi-omics Phenotyping to Predict Response, Resistance and Recurrence to Adjuvant Atezolizumab plus Bevacizumab in Resected Hepatocellular Carcinoma (HCC)(EMPHASIS)(NCT05516628) AHCC13: Liquid Biopsy based Identification of Predictive Biomarkers of Response in Intermediate/Locally Advanced HCC receiving Y90 +/- Atezolizumab plus Bevacizumab (NCT05377034) |
---|---|
Status |
Recruiting |
Contributing Principal Investigators and Centres |
Singapore Adrian Chiow (Changi General Hospital), Toh Han Chong (National Cancer Centre), Chee Cheng Ean (National University Hospital), Kam Juinn Huar (Sengkang General Hospital), Brian Goh (Singapore General Hospital), samol jens (Tan Tock Seng Hospital) Up to 11 overseas sites in Asia-Pacific |
Thematic Principal Investigators |
Theme 1: Deep Phenotyping and Correlation with Clinical Responses to Therapy Name: Pierce Chow Name: Patrick Tan Theme 2: Elucidating Spatial Distribution of Biomarkers at Single-cell Resolution Name: Vinay Tergaonkar Theme 3: Translational and Functional Immunomics Name: Toh Han Chong Theme 4: Pre-Clinical Disease Modelling and Target Discovery Name: Tam Wai Leong Name: Edward Chow Theme 5: Data Architecture, Data Security and Data Science Applications Name: Roger Vaughan |
Protocol Chair |
Pierce Chow |
AHCC11 |
Prospective Cohort Study of Changes in Circulatory micro-RNA after Surgical Resection of Hepatocellular Carcinoma (PROSECT) |
---|---|
Status |
Recruiting |
Contributing Principal Investigators and Centres |
Singapore Adrian Chiow (Changi General Hospital), Pierce Chow (National Cancer Centre), Glenn Bonney (National University Hospital), Brian Goh (Singapore General Hospital), Kam Juinn Huar (Sengkang General Hospital), Vishalkumar G. Shelat (Tan Tock Seng Hospital) |
Protocol Chair |
Pierce Chow |
AHCC10 |
Early Detection of Hepatocellular Carcinoma: miRNA, microbiome and imaging biomarkers in the evolution of chronic liver disease in a high-risk prospective cohort (ELEGANCE) (NCT04965259) |
---|---|
Status |
Recruiting |
Contributing Principal Investigators and Centres |
Singapore Eugene Wong Yu Jun (Changi General Hospital), Toh Han Chong (National Cancer Centre), Lee Guan Huei (National University Hospital), Jason Chang (Singapore General Hospital), Chong Oi Fong (SingHealth Polyclinics – Bedok), Sabrina Wee (SingHealth Polyclinics – Bukit Merah), Tan Kee Tung (SingHealth Polyclinics – Marine Parade), Ong Kok Kiong (SingHealth Polyclinics – Outram), Tan Ngiap Chuan (SingHealth Polyclinics – Pasir Ris), Yeap Xin Yi (SingHealth Polyclinics – Punggol), Choo Han Jun (SingHealth Polyclinics – Sengkang), Sulaiha Binte Ithnin (SingHealth Polyclinics – Tampines), Marianne De Roza (Sengkang General Hospital), Yang Wei Lyn (Tan Tock Seng Hospital) |
Protocol Chair |
Pierce Chow |
AHCC09 |
A multi-national, double-blind, placebo-controlled, parallel randomized arms, phase II trial to compare the safety and efficacy of SIRT-Y90 followed by atezolizumab plus bevacizumab versus SIRT-Y90 followed by placebo in patients with locally advanced hepatocellular carcinoma (HCC) (STRATUM) (NCT05377034) |
---|---|
Status |
Recruiting |
Contributing Principal Investigators and Centres |
Singapore Pierce Chow (National Cancer Centre), Toh Han Chong (National Cancer Centre), Chee Cheng Ean (National University Hospital) up to 11 overseas sites from: Taiwan (TBC) South Korea (TBC) China (TBC) |
Protocol Chair |
Pierce Chow |